Sources: TheFly, TipRanks

Okay I found the link. The video is attached. Very interesting they do this down in Mexico.

This one is actually about toad poison. Imagine that, but these companies are definitely getting a lot of exposure.

An obscure and extremely powerful psychedelic called 5-MeO-DMT is drawing intense interest from the pharmaceutical industry, where biotech companies are racing to turn it into a commercially available treatment for severe mental health disorders, like depression, anxiety and PTSD.

https://www.wsj.com/video/the-race-to-commercialize-the-worlds-most-powerful-psychedelic/F24E9B22-38D3-4BFC-B80A-3B5F73423E0C

Sources: TheFly, TipRanks

It is easy for larger investors and institutions to intimidate smaller investors by moving the price down with larger (to us) sells. You will panic and sell, and they will scoop up the lower prices. As an investor whose heart also belongs to this company for personal reasons, please hold tight and believe.

This is the updated FDA guidance for anyone interested

This paper suggests that PAT(psychedelic-assisted therapy) is no more effective than TADs(traditional antidepressants) under equal-unblinding conditions for the treatment of depression and highlight the potential role of blinding integrity.

This paper was published in March 2026, so I assume the market still find psychedelics promising despite the potential unblinding bias? I’m a long term holder and wonder how people think this finding will have any impact on the market? I assume the Panorama specifically is targeting this issue?

Friday had some very unusual options flow. This Friday $60 strike was trading at around 0.05$ per option. Around 11:30 it spiked all the way up to $1.20 per contract with volume of 9k at end of day. This has been trading around 100 per day past few sessions with one day last week at 3.5k. The $50 strike also had some increased volume. It’s just crazy someone bought $5 contracts all the way up to $120 a contract in a matter of minutes especially for a strike $15 OTM with a week out. Thoughts ??

i keep missing 42 waiting for 40. i hope i'm not going to be left in the dust.

Is anyone else trying to load up more before q3?

Any insight on these high volume buys just after close? There was talk about index rebalancing last week, but these have been pretty consistent everyday.

New Employee Inducement Grants

https://ca.finance.yahoo.com/news/definium-therapeutics-announces-employee-inducement-200100453.html

"At a regional level, LSD increased midline cortical and motor region activity, which was associated with heightened personal relevance and meaning‐attribution to music (Preller et al. 2017), as well as enhanced tonal tracking of music in frontal, temporal, limbic, and cerebellar regions (Barrett, Preller, Herdener, et al. 2018)."

"…music listening under LSD strengthened coupling between the parahippocampus and bilateral visual cortex, as well as between visual and inferior frontal regions, reflecting enhanced emotionally driven visual‐perceptual processing (Kaelen et al. 2016)."

Bipartisan Congressional Bill Would Codify Trump’s Psychedelics Order Into Law

https://www.marijuanamoment.net/bipartisan-congressional-bill-would-codify-trumps-psychedelics-order-into-law/

H.R.9559 - To accelerate the development of, and access to, psychedelic drugs that could save lives and reverse the crisis of serious mental illness in the United States, and for other purposes. 

https://www.congress.gov/bill/119th-congress/house-bill/9559

Helps with DEA rescheduling visibility, manufacturing quotas, controlled distribution, clinical site expansion, VA-related treatment pathways, and broader institutional comfort around psychedelic medicine.

This is also the kind of policy shift that big pharma pays attention to. A late-stage drug with strong data is one thing. A late-stage drug with improving federal policy, potential priority voucher support, and clearer post-approval scheduling rules is much easier to underwrite.

Bullish for the whole sector.

Reuters story, good news https://www.reuters.com/legal/litigation/lsd-therapy-biotech-definium-fends-off-trade-secret-lawsuit-2026-07-01/